Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Incyte
Pharma
Mirum scores FDA approval for ultra-rare disorder
Rare disease pharma Mirum scored an approval for its ultra-rare bone lesion treatment it bought from Incyte.
Donavyn Coffey
Sep 25, 2026 4:10pm
FDA approves label expansion for PharmaEssentia's Besremi
Aug 31, 2026 8:25am
Pfizer plots Litfulo vitiligo filings, pressuring Incyte, AbbVie
Jul 30, 2026 2:15pm
Incyte expects Opzelura to cross $1B in 2026
Jul 29, 2026 10:30am
Europe's CHMP reverses endorsement of Amgen's Tavneos
Jun 26, 2026 11:07am
CMS, Incyte settle lawsuit on classification of Opzelura
Jun 23, 2026 1:32pm
